Trial to Evaluate Beta-Lactam Antimicrobial Therapy of Community Acquired Pneumonia in Children
Status:
Completed
Trial end date:
2019-12-16
Target enrollment:
Participant gender:
Summary
This is a multi-center, randomized, double-blind, placebo-controlled, superiority clinical
trial will test the effectiveness of short (5-day) vs.standard (10-day) course therapy in
children who are diagnosed with CAP and initially treated in outpatient clinics, urgent care
facilities, and emergency departments. Primary objective is to compare the composite overall
outcome (Desirability of Outcome Ranking, DOOR) among children 6-71 months of age with CAP
assigned to a strategy of short course (5 days) vs standard course (10 days) outpatient
beta-lactam therapy at Outcome Assessment Visit #1 (Study Day 8 +/- 2 days)
Phase:
Phase 4
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)